

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1614
Brinkmann, Volker Et Al. EXAMINER: Rae Charlesworth E
INTERNATIONAL APPLICATION NO: PCT/EP2004/014436
FILED: DECEMBER 17, 2004
U.S. APPLICATION NO: 10/583106
35 USC §371 DATE: JULY 19, 2006
For: Use Of Sphingosine-1-Phosphate (S1p) Receptor Agonists For The
Treatment Of Brain Degenerative Diseases

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

- ☒ supplemental to the Information Disclosure Statement filed August 18, 2006.
- ☒ before the mailing date of a first Office action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required.


If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134 in the name of Novartis.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

- ☒ Copies of the references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Cozette McAvoy
Attorney for Applicant
Reg. No. 60,457

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9273

Date: *18th June 2019*